In thyroid carcinomas, MYC overexpression develops by various means, including MYC amplification or rearrangements, BRAFv600e mutation interactions, specific long noncoding RNA dysregulation, increased BRD4 protein production, and abnormal TERT expression, among others [25, 27–31]. This evidence concerns the gene TERT and thyroid gland carcinoma.